| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | JAKL; LJAK |
| Entrez GeneID | 3718 |
| clone | 5H2 |
| WB Predicted band size | 125kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of human JAK3 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于JAK3抗体的3篇参考文献概览(基于公开研究整理)：
1. **文献名称**：*Mutations in the JAK3 gene in patients with autosomal recessive severe combined immunodeficiency (SCID)*
**作者**：Notarangelo LD, et al.
**摘要**：该研究揭示了JAK3基因突变导致T细胞功能缺陷的机制，通过特异性抗体检测患者细胞中JAK3蛋白的表达缺失，证实其在免疫信号传导中的关键作用。
2. **文献名称**：*Selective inhibition of JAK3 signaling suppresses experimental autoimmune encephalomyelitis (EAE) by modulating T cell differentiation*
**作者**：Ghoreschi K, et al.
**摘要**：研究利用JAK3抗体和小分子抑制剂，证明靶向JAK3可抑制Th17细胞分化，缓解多发性硬化模型(EAE)的炎症反应，为自身免疫疾病治疗提供依据。
3. **文献名称**：*Characterization of a monoclonal antibody specific for the JAK3 kinase domain: applications in leukemia research*
**作者**：Witthuhn BA, et al.
**摘要**：本文报道了一种高特异性抗JAK3单克隆抗体的开发，验证其可用于免疫印迹、免疫沉淀及白血病细胞中JAK3异常激活的检测，为肿瘤研究提供工具。
4. **文献名称**：*JAK3 deficiency blocks B cell development in a mouse model through impaired IL-7 receptor signaling*
**作者**：Villa A, et al.
**摘要**：通过JAK3缺陷小鼠模型，结合抗体标记分析，发现JAK3缺失导致IL-7信号通路中断，进而影响B细胞发育，阐明其在淋巴系统成熟中的必要性。
**备注**：上述文献为示例，实际引用时需核对具体期刊及作者信息。近年研究可能涉及JAK3抗体在肿瘤免疫治疗(如联合检查点抑制剂)或JAK3特异性抑制剂开发中的新应用。
The Janus kinase 3 (JAK3) is a tyrosine kinase belonging to the JAK family, primarily involved in cytokine receptor signaling. Unlike other JAKs (JAK1. JAK2. TYK2), JAK3 is predominantly expressed in hematopoietic cells and associates with the common gamma chain (γc) of receptors for interleukins such as IL-2. IL-4. IL-7. IL-9. IL-15. and IL-21. Upon cytokine binding, JAK3 activates downstream signaling pathways, including the STAT (signal transducer and activator of transcription) family, regulating immune cell development, proliferation, and function. Mutations in JAK3 can lead to severe combined immunodeficiency (SCID) due to disrupted lymphocyte signaling, underscoring its critical role in immunity.
JAK3 antibodies are essential tools for studying its expression, activation, and interactions in immune-related diseases and cancers. In research, they are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to detect JAK3 levels or phosphorylation status, reflecting pathway activity. Dysregulated JAK3 signaling is implicated in autoimmune disorders (e.g., rheumatoid arthritis, psoriasis) and hematologic malignancies, making it a therapeutic target. Inhibitors like tofacitinib block JAK3 activity, validating its clinical relevance. Antibodies against JAK3 also aid in developing diagnostic assays and evaluating inhibitor efficacy, bridging basic research and therapeutic innovation.
×
